Stocks were sharply lower Monday afternoon on concerns about the competitive threat that China poses in the race to develop artificial intelligence.

In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3% ...

Novo's U.S. and Europe-listed stocks leapt. Shares of rival Eli Lilly (LLY) also rallied. 🔎 Affirm (AFRM): The "buy-now-pay-later" lender secured $750 million in funding from insurer Liberty ...

US PMI data came in more mixed than expected, to little effect. The Dow Jones Industrial Average (DJIA) churned into a soft backpedal on Friday, testing down around 200 points on a slow trading day.

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Thursday’s gains put the Dow Jones Industrial Average on pace to close in the green for a fifth straight session, and the major equity index has gained ground in all but one of the last nine ...

The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the market, since its components' performance is indicative of what's happening ...

The SPDR Dow Jones Industrial Average ETF Trust (DIA) tracks the Dow Jones Industrial Average, offering exposure to 30 prominent U.S. stocks. It uses a price-weighted index method and cannot ...

outpacing Eli Lilly's own drug in early comparisons. Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average weight loss of 22% ...

Ich bin damit einverstanden, dass mir die BurdaForward GmbH, St. Martin Straße 66, 81541 München, regelmäßig News zu den oben ausgewählten Themenbereichen per E-Mail zusendet. Ich bin ...